- Home
- XOMAP vs ESNT Comparison
XOMAP vs ESNT Comparison
Compare XOMAP & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- ESNT
- Stock Information
- Founded
- XOMAP N/A
- ESNT 2008
- Country
- XOMAP United States
- ESNT Bermuda
- Employees
- XOMAP 13
- ESNT N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- ESNT Property-Casualty Insurers
- Sector
- XOMAP Health Care
- ESNT Finance
- Exchange
- XOMAP Nasdaq
- ESNT Nasdaq
- Market Cap
- XOMAP N/A
- ESNT N/A
- IPO Year
- XOMAP N/A
- ESNT 2013
- Fundamental
- Price
- XOMAP $26.78
- ESNT $59.61
- Analyst Decision
- XOMAP
- ESNT Buy
- Analyst Count
- XOMAP 0
- ESNT 6
- Target Price
- XOMAP N/A
- ESNT $65.67
- AVG Volume (30 Days)
- XOMAP N/A
- ESNT 681.6K
- Earning Date
- XOMAP N/A
- ESNT 11-07-2025
- Dividend Yield
- XOMAP N/A
- ESNT 2.08%
- EPS Growth
- XOMAP N/A
- ESNT N/A
- EPS
- XOMAP N/A
- ESNT 6.85
- Revenue
- XOMAP N/A
- ESNT $1,268,306,000.00
- Revenue This Year
- XOMAP N/A
- ESNT $4.27
- Revenue Next Year
- XOMAP N/A
- ESNT $1.47
- P/E Ratio
- XOMAP N/A
- ESNT $8.68
- Revenue Growth
- XOMAP N/A
- ESNT 5.28
- 52 Week Low
- XOMAP N/A
- ESNT $51.61
- 52 Week High
- XOMAP N/A
- ESNT $65.90
- Technical
- Relative Strength Index (RSI)
- XOMAP 61.04
- ESNT 41.44
- Support Level
- XOMAP $26.13
- ESNT $58.46
- Resistance Level
- XOMAP $26.60
- ESNT $61.02
- Average True Range (ATR)
- XOMAP 0.13
- ESNT 0.98
- MACD
- XOMAP 0.02
- ESNT -0.31
- Stochastic Oscillator
- XOMAP 100.00
- ESNT 19.07
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.